Готові списки джерел за темами / (H1N1) 2009 Monovalent Vaccine

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій

Добірка наукової літератури з теми "(H1N1) 2009 Monovalent Vaccine"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "(H1N1) 2009 Monovalent Vaccine".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "(H1N1) 2009 Monovalent Vaccine"

N, K. Mishra* J. R. Panda Santanu Kumar Hotta. "SWINE FLU (2009 H1N1 INFLUENZA) AND IT'S MONOVALENT VACCINATION." Indo American Journal of Pharmaceutical Sciences 04, no. 11 (2017): 4451–54. https://doi.org/10.5281/zenodo.1066275.

Повний текст джерела

Анотація:

Swine flu (2009 H1N1) is a mutational modified strain of the influenza virus. Many countries have been affected with this virus globally and it has been declared a pandemic influenza strain. 2009 H1N1 virus is a communicable disease which spreads from person to person through coughing, sneezing, nasal secretion and handling of objects which is contaminated with the virus. It is an ideal way to prevent swine flu by taking of early vaccination. Influenza A (H1N1) 2009 Monovalent vaccine is an inactivated influenza virus indicated for active immunization of persons age 6months and older against i

Стилі APA, Harvard, Vancouver, ISO та ін.

Song, Joon Young, Hee Jin Cheong, Yu Bin Seo, et al. "Comparison of the Long-Term Immunogenicity of Two Pandemic Influenza A/H1N1 2009 Vaccines, the MF59-Adjuvanted and Unadjuvanted Vaccines, in Adults." Clinical and Vaccine Immunology 19, no. 5 (2012): 638–41. http://dx.doi.org/10.1128/cvi.00026-12.

Повний текст джерела

Анотація:

ABSTRACTSince the first reports of the A/H1N1 virus in April 2009, the pandemic influenza virus spread globally and circulated for a long time. The primary method for the control of influenza is vaccination, but levels of influenza vaccine-induced antibody are known to decline rapidly during a 6-month period. In adults aged 18 to 64 years, we compared the long-term immunogenicity of two of the influenza A/H1N1 2009 monovalent vaccines, 3.75-μg MF59-adjuvanted vaccine and 15-μg unadjuvanted vaccine. The serum hemagglutinin inhibition (HI) titers were determined prevaccination and at 1, 6, and 1

Стилі APA, Harvard, Vancouver, ISO та ін.

Song, Joon Young, Hee Jin Cheong, Yu Bin Seo, et al. "Long-Term Immunogenicity of the Pandemic Influenza A/H1N1 2009 Vaccine among Health Care Workers: Influence of Prior Seasonal Influenza Vaccination." Clinical and Vaccine Immunology 20, no. 4 (2013): 513–16. http://dx.doi.org/10.1128/cvi.00725-12.

Повний текст джерела

Анотація:

ABSTRACTHealth care workers (HCWs) are at great risk of influenza infection and transmission. Vaccination for seasonal influenza is routinely recommended, but this strategy should be reconsidered in a pandemic situation. Between October 2009 and September 2010, a multicenter study was conducted to assess the long-term immunogenicity of the A/H1N1 2009 monovalent influenza vaccine among HCWs compared to non-health care workers (NHCWs). The influence of prior seasonal influenza vaccination was also assessed with respect to the immunogenicity of pandemic H1N1 influenza vaccine. Serum hemagglutini

Стилі APA, Harvard, Vancouver, ISO та ін.

Greenberg, Michael E., Michael H. Lai, Gunter F. Hartel, et al. "Response to a Monovalent 2009 Influenza A (H1N1) Vaccine." New England Journal of Medicine 361, no. 25 (2009): 2405–13. http://dx.doi.org/10.1056/nejmoa0907413.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Arya, Subhash C., and Agarwal Nirmala. "Influenza A (H1N1) 2009 monovalent vaccine: Laboratory confirmation of vaccine breakdowns." Vaccine 27, no. 49 (2009): 6808. http://dx.doi.org/10.1016/j.vaccine.2009.09.012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Clark, Tristan W., Manish Pareek, Katja Hoschler, et al. "Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine." New England Journal of Medicine 361, no. 25 (2009): 2424–35. http://dx.doi.org/10.1056/nejmoa0907650.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Schauer, Stephanie L., Daniel J. Hopfensperger, Matthew J. Verdon, Thomas R. Maerz, Gerald W. Gabor, and Jeffrey P. Davis. "An Immunization Information System to Meet Evolving Needs During the 2009-2010 Influenza A (H1N1) Vaccination Campaign." Disaster Medicine and Public Health Preparedness 6, no. 4 (2012): 402–7. http://dx.doi.org/10.1001/dmp.2012.64.

Повний текст джерела

Анотація:

ABSTRACTIn 2009, a monovalent H1N1 influenza (H1N1) vaccine was manufactured in response to the pandemic of 2009 influenza A (H1N1) virus infection that emerged earlier in the year. The overall allocation of the H1N1 vaccine to the states was the purview of the federal government; thereafter, the states were accountable for distributing and reporting the number of doses of H1N1 vaccine administered weekly. This report describes how the Wisconsin Immunization Registry (WIR) was updated and used during the H1N1 immunization campaign and its role in meeting the federal H1N1 immunization reporting

Стилі APA, Harvard, Vancouver, ISO та ін.

O'Donnell, Christopher D., Amber Wright, Leatrice Vogel, Kobporn Boonnak, John J. Treanor, and Kanta Subbarao. "Humans and Ferrets with Prior H1N1 Influenza Virus Infections Do Not Exhibit Evidence of Original Antigenic Sin after Infection or Vaccination with the 2009 Pandemic H1N1 Influenza Virus." Clinical and Vaccine Immunology 21, no. 5 (2014): 737–46. http://dx.doi.org/10.1128/cvi.00790-13.

Повний текст джерела

Анотація:

ABSTRACTThe hypothesis of original antigenic sin (OAS) states that the imprint established by an individual's first influenza virus infection governs the antibody response thereafter. Subsequent influenza virus infection results in an antibody response against the original infecting virus and an impaired immune response against the newer influenza virus. The purpose of our study was to seek evidence of OAS after infection or vaccination with the 2009 pandemic H1N1 (2009 pH1N1) virus in ferrets and humans previously infected with H1N1 viruses with various antigenic distances from the 2009 pH1N1

Стилі APA, Harvard, Vancouver, ISO та ін.

ENGLUND, H., H. CAMPE, and W. HAUTMANN. "Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria, Germany, 2010/2011 season." Epidemiology and Infection 141, no. 9 (2012): 1807–15. http://dx.doi.org/10.1017/s0950268812002282.

Повний текст джерела

Анотація:

SUMMARYWe estimated the vaccine effectiveness (VE) of trivalent and monovalent influenza vaccines, respectively, against laboratory-confirmed influenza infections in patients with influenza-like illness who visited physicians participating in the Bayern Influenza Sentinel in Bavaria, Germany during 2010/2011. Swab specimens were analysed for influenza A(H1N1)pdm09, A(H3) and B by PCR. VE was estimated using the test-negative case-control study design and logistic regression. In total, 1866 patients (790 cases, 1076 controls) were included. The VE of trivalent vaccines administered in season 20

Стилі APA, Harvard, Vancouver, ISO та ін.

U., Anuja, Rajasi R. S., Ratheesh K. H., VijayaKumar K., and Amar Fettil. "Seroconversion following H1N1 influenza vaccination among health care personnel in South Kerala, India." International Journal Of Community Medicine And Public Health 4, no. 2 (2017): 428. http://dx.doi.org/10.18203/2394-6040.ijcmph20170267.

Повний текст джерела

Анотація:

Background: Health care workers were prioritized by World Health Organization (WHO) for H1N1 vaccination during 2009 swine influenza pandemic following which in Kerala, a total of 72,000 people mostly health care personnel were immunized with a single dose of inactivated split influenza monovalent H1N1 vaccine in 2010. The present study was carried out with the objective to find out the proportion of health care workers seroconverted in Kerala following H1N1 vaccination.Methods:A cross-sectional study conducted in three districts of Kerala. Blood samples collected from 193 health staffs were a

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "(H1N1) 2009 Monovalent Vaccine"

Nguyen, Trang. "Acceptance of an Emergently Released Vaccine by the General Public: 2009 H1N1 Influenza Pandemic Vaccine." Thèse, Université d'Ottawa / University of Ottawa, 2012. http://hdl.handle.net/10393/23247.

Повний текст джерела

Анотація:

The recent experience with the 2009 H1N1 pandemic has drawn attention to the need to better understand the public’s response to emergently released vaccines (ERV). This study applied a mixed methods approach to examine the causal pathways underlying the vaccination behaviour during a public health emergency. The integrated evidence from empirical and theoretical-based findings highlights a number of factors to consider in interventions to improve vaccination rates with an ERV. These factors include: 1) providing clear risk messages around the disease and the ERV, 2) improving accessibilit

Стилі APA, Harvard, Vancouver, ISO та ін.

Fielding, James. "Influenza epidemiology and vaccine effectiveness following the 2009 pandemic." Phd thesis, 2014. http://hdl.handle.net/1885/151805.

Повний текст джерела

Анотація:

Influenza A(H1N1)pdm09 was identified in April 2009 and spread rapidly around the globe. The public health response in Victoria was undertaken in accordance with the Australian Health Management Plan for Pandemic Influenza (AHMPPI) and included intensive case follow up, school closure, antiviral distribution and a vaccination program. However, evidence soon emerged that most cases were relatively mild compared to previous pandemics. This thesis sought to assess how the epidemiology of influenza A(H1N1)pdm09 differed from expectations in pandemic planning and how the control measures of school

Стилі APA, Harvard, Vancouver, ISO та ін.

Chen, Juine-Ruey, and 陳俊叡. "The Monoglycosylated Hemagglutinin from Seasonal Influenza H1N1 Is an Effective Vaccine with CrossProtective Immunity against Pandemic 2009 H1N1 Virus Infection in Mice." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/66305530721684589777.

Повний текст джерела

Анотація:

博士<br>國立陽明大學<br>生化暨分子生物研究所<br>98<br>Influenza pandemics occur when influenza hemagglutinins (HA) are little recognized by immunity and the viruses transmit efficiently from human to human. HA is the major viral surface glycoprotein that binds to specific sialylated glycan receptors in the respiratory tract and allows the virus to enter the cell. It has been recognized as the key antigen in the host immune response to influenza virus in both natural infection and vaccination. We have shown that HA with a single N-linked N-acetylglucosamine (GlcNAc) at each glycosylation sites (monoglycosylated

Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "(H1N1) 2009 Monovalent Vaccine"

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. H1N1 preparedness: An overview of vaccine production and distribution : joint hearing before the Subcommittee on Health and the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, first session, November 18, 2009. U.S. G.P.O., 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

H1N1 flu, 2009: Hearings before the Committee on Homeland Security and Governmental Affairs, United States Senate, of the One Hundred Eleventh Congress, first session : April 29, 2009, coordinating the federal response; September 21, 2009, protecting our community: field hearing in Hartford, CT; October 21, 2009, monitoring the nation's response; November 17, 2009, getting the vaccine to where it is most needed. U.S. G.P.O., 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lundgren, Britta, and Martin Holmberg. Pandemic flus and vaccination policies in Sweden. Manchester University Press, 2017. http://dx.doi.org/10.7228/manchester/9781526110886.003.0011.

Повний текст джерела

Анотація:

During 2010 an increasing incidence of narcolepsy in children and adolescents was reported in Sweden and Finland, associated with the pandemic vaccine Pandemrix. Vaccination has since the 1940s been seen as a magic bullet to protect from flu. During past influenza pandemics in Sweden, the vaccine was, however, either absent or in short supply. Since the pandemic 2009-10 – caused by the Influenza A(H1N1) virus – production increased and mass vaccination campaigns were launched in many countries. Sweden was the most successful, with over sixty per cent coverage in what became the largest public

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "(H1N1) 2009 Monovalent Vaccine"

Halabi, Sam F. "Obstacles to pH1N1 Vaccine Availability." In The Public Health Response to 2009 H1N1. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780190209247.003.0012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Wayne, Marta L., and Benjamin M. Bolker. "Influenza." In Infectious Disease: A Very Short Introduction, 2nd ed. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/actrade/9780192858511.003.0003.

Повний текст джерела

Анотація:

Abstract Influenza, or flu, has caused more deaths than any single disease outbreak since the 14th-century bubonic plague. Twenty to 50 million people worldwide died from the 1918 Spanish Flu, which was an H1N1 strain similar to the one that caused the 2009 pandemic. ‘Influenza’ considers the control of flu transmission through hand hygiene and masking (reducing encounter), through vaccination (reducing compatibility), or ideally by a combination of both. Because flu mutates rapidly and shuffles its genome, the virus is constantly evolving. Therefore, immunity based either on vaccination or na

Стилі APA, Harvard, Vancouver, ISO та ін.

Eccleston-Turner, Mark, and Harry Upton. "The Procurement of a COVID-19 Vaccine in Developing Countries: Lessons from the 2009 H1N1 Pandemic." In Public Procurement Regulation in (a) Crisis? Hart Publishing, 2021. http://dx.doi.org/10.5040/9781509943067.ch-013.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

van Santen, Rutger, Djan Khoe, and Bram Vermeer. "Preparing for Pandemics." In 2030. Oxford University Press, 2010. http://dx.doi.org/10.1093/oso/9780195377170.003.0030.

Повний текст джерела

Анотація:

The first draft of this chapter was written before the pandemic alert for the 2009 flu was launched. Since then, terms such as swine flu, Mexican flu, or H1N1 were constantly in the headlines. We witnessed the first really worldwide outbreak of a new influenza strain. Events went faster than we foresaw in our original text. We had started the chapter with an imaginary scenario of an outbreak in 2013 not in Mexico but in the East Java, Indonesia, city of Malang. It was not really meant as a prediction but merely a little story to show the consequences of an outbreak. We wanted to show how disru

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "(H1N1) 2009 Monovalent Vaccine"

Aoki, Nobumasa, Nao Koshio, Takashi Hasegawa, et al. "The Efficacy Of Pandemic H1N1 (2009) Influenza Vaccine Against Asthma Patients Using Questionnaire Survey In Japan." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a1797.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!